The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy

International Journal of Cancer

Volumn 124, Issue 12, 2009, Pages 2899-2904

  Savic, Spasenija ^a,k   Zlobec, Inti ^a   Thalmann, George N ^b   Engeler, Daniel ^c   Schmauss, Martina ^d   Lehmann, Kurt ^e   Mattarelli, Gianfranco ^f   Eichenberger, Tobias ^f   Dalquen, Peter ^a   Spieler, Peter ^g   Schoenegg, Reń ^g   Gasser, Thomas C ^h   Sulser, Tullio ^h,l   Forster, Thomas ^h,m   Zellweger, Tobias ⁱ   Casella, Roberto ^j   Bubendorf, Lukas ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

^d CANTONAL HOSPITAL AARAU   (Switzerland)

^e Kantonsspital Baden   (Switzerland)

^f Urological Practice   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h UNIVERSITY OF BASEL   (Switzerland)

ⁱ St Claraspital AG   (Switzerland)

^j Hospital Center Biel   (Switzerland)

^k JOHNS HOPKINS HOSPITAL   (United States)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m KANTONSSPITAL   (Switzerland)

more..

Author keywords

Bacillus Calmette Gu rin; Cytology; Fluorescence in situ hybridization; Nonmuscle invasive urothelial bladder cancer

Indexed keywords

BCG VACCINE; EPIRUBICIN; DNA; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CYTODIAGNOSIS; CANCER RELAPSE; CARCINOMA IN SITU; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9P; CHROMOSOME ABERRATION; CLINICAL TRIAL; DRUG INSTILLATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; BLADDER TUMOR; CANCER INVASION; CYTODIAGNOSIS; GENETICS; INCIDENCE; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; PAPILLARY CARCINOMA; PROSPECTIVE STUDY; TUMOR RECURRENCE; UTILIZATION REVIEW;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; CHROMOSOME ABERRATIONS; CYTODIAGNOSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 65649113931     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24258     Document Type: Article

References (24)

1. Josephson D, Pasin E, Stein JP. Superficial bladder cancer. II. Management. Expert Rev Anticancer Ther 2007;7:567-581
2. Nieder AM, Brausi M, Lamm D, O'Donnell M, Tomita K, Woo H, Jewett MA. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005;66:108-125 (Pubitemid 43049612)
3. van der Meijden AP, Sylvester R, Oosterlinck W, Solsona E, Boehle A, Lobel B, Rintala E. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005;48:363-371 (Pubitemid 41188389)
4. Sylvester RJ, van der MA, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970
5. Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994;151:31-5; discussion 5-6. (Pubitemid 24046930)
6. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 2004;172:70-75
7. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, et al. Prognostic factors in patients with nonmuscle-invasive bladder cancer treated with Bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53:992-1002.
8. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-75; discussion 475-477 (Pubitemid 43259554)
9. Maier U, Simak R, Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 1995;48:314-317
10. Lopez-Beltran A, Luque RJ, Mazzucchelli R, Scarpelli M, Montironi R. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol 2002;55:641-647 (Pubitemid 34970083)
11. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-1954
12. Jones JS. DNA-based molecular cytology for bladder cancer surveillance. Urology 2006;67:35-45; discussion 45-47 (Pubitemid 43344220)
13. Sobin LH, Wittekind Ch. International Union Against Cancer (UICC): TNM classification of malignant tumors, 6th ed. New York: Wiley-Liss, 2002.
14. Zellweger T, Benz G, Cathomas G, Mihatsch MJ, Sulser T, Gasser TC, Bubendorf L. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006;119:1660-1665 (Pubitemid 44258773)
15. Glatz K, Willi N, Glatz D, Barascud A, Grilli B, Herzog M, Dalquen P, Feichter G, Gasser TC, Sulser T, Bubendorf L. An international telecytologic quiz on urinary cytology reveals educational deficits and absence of a commonly used classification system. Am J Clin Pathol 2006;126:294-301. (Pubitemid 44162577)
16. Bubendorf L, Grilli B. UroVysion multiprobe FISH in urinary cytology. Methods Mol Med 2004;97:117-131
17. Guy L, Savareux L, Molinie V, Botto H, Boiteux JP, Lebret T. Should bladder biopsies be performed routinely after Bacillus Calmette-Guerin treatment for high-risk superficial transitional cell cancer of the bladder? Eur Urol 2006;50:516-20; discussion 520.
18. Zurkirchen MA, Sulser T, Gaspert A, Hauri D. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int 2004;72:99-102. (Pubitemid 38223792)
19. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, Blute MM, Lieber MM, Zincke H, Halling KC. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173:401-404
20. Mengual L, Marin-Aguilera M, Ribal MJ, Burset M, Villavicencio H, Oliver A, Alcaraz A. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with Bacillus Calmette-Guerin therapy. Eur Urol 2007;52:752-759 (Pubitemid 47126159)
21. Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H, Marberger M. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol 1998;159:265-269
22. Raitanen MP. The role of BTA stat test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 2008;26:45-50.
23. Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2008;179:2164-2169
24. Kipp BR, Halling KC, Campion MB, Wendel AJ, Karnes RJ, Zhang J, Sebo TJ. Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal. J Urol 2008;179:1296-301; discussion 301.